Is LFCR or ORGO more undervalued in 2026?

CirclFi compares Lifecore Biomedical, Inc. (LFCR) and Organogenesis Holdings Inc. (ORGO) using 13 institutional-grade valuation models. LFCR has a Quality of Company score of 4.9/10 while ORGO scores 7.2/10.

Which is a better buy — LFCR or ORGO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do LFCR and ORGO valuations compare?

LFCR at $4.97 and ORGO at $2.62 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

LFCR vs ORGO Valuation Comparison 2026 — Intrinsic Value Analysis

LFCR

Drug Manufacturers - Specialty & Generic

Lifecore Biomedical, Inc.

Quality

4.9

out of 10

Value Trap

SAFE

Price

$4.97

Last close

Models

7/13

Active

ORGO

Drug Manufacturers - Specialty & Generic

Organogenesis Holdings Inc.

Quality

7.2

out of 10

Value Trap

SAFE

Price

$2.62

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	LFCR Fair Value	LFCR Upside	ORGO Fair Value	ORGO Upside
Bayesian DCF	Intrinsic	—	—	$0.05	-98.3%
Earnings Power Value	Intrinsic	—	—	$0.12	-95.2%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$0.61	-86.0%	$2.80	+5.1%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$5.74	+15.4%	$2.05	-21.6%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for LFCR vs ORGO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LFCR vs ORGO — Which Stock Is More Undervalued?

ORGO scores higher with a 7.2/10 quality rating vs LFCR's 4.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lifecore Biomedical, Inc. (LFCR) and Organogenesis Holdings Inc. (ORGO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LFCR currently trades at $4.97 with a QOC of 4.9/10, while ORGO trades at $2.62 with a QOC of 7.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).